Having HIV almost doubles the risk of liver fibrosis, according to European research published in the online edition of the Journal of Infectious Diseases. Investigators in Denmark and the Netherlands compared rates of liver fibrosis between people living with HIV and people without HIV. Importantly, none of the participants had hepatitis B virus (HBV) or… Read More »
To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people who inject drugs, an analysis of Scottish surveillance data published in HIV Medicine shows. Scotland has a high prevalence of hepatitis C among people with… Read More »
Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians.… Read More »
Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) for the treatment of people with chronic hepatitis C infection (HCV) as young as 6 years of age or weighing at… Read More »
As the U.S. population living with hepatitis C virus (HCV) ages, the safety and efficacy of direct-acting antiviral (DAA) treatment for the senior population is an important concern. The bulk of those living with HCV in the United States are baby boomers—those born between 1945 and 1965—about half of whom are over age 65 and… Read More »